Wezlana™

INN: ustekinumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Biosimilar

Delivery Route

Intravenous infusion, then subcutaneous injection

Health Canada Approval

2023

Storage

Subcutaneous injection: refrigerate between 2 and 8°C, keep in original vials standing upright, do not freeze, do not shake, may be stored at room temperature (up to 30°C) for a single period of up to 30 days. Intravenous infusion: only a healthcare professional should prepare and administer the medicine.

Use in Older Adults (65+)

May be used among those 60+; closely monitor for skin cancer.

Pregnancy Indication

No pattern of major birth defects has been observed; only use if benefits outweigh risks.

Breastfeeding Indication

Effects unknown; please consult your doctor.

Pediatric Indication

Safety and efficacy not established.

Learn More

View the Wezlana™ product monograph.